Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 8, pp 1939–1948 | Cite as

Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis

  • Xueliang Zhou
  • Dechao Jiao
  • Mengmeng Dou
  • Jianjian Chen
  • Zhaonan Li
  • Yahua Li
  • Juanfang Liu
  • Xinwei HanEmail author
Review – Cancer Research

Abstract

Objective

Some studies have shown that the methylation status of the GSTP1 gene promoter is related to the incidence of prostate cancer, but this finding is still controversial. The aim of this study was to evaluate the association between glutathione-S-transferase p1 (GSTP1) promoter methylation and the incidence of prostate cancer.

Methods

The Medline, Embase, Web of Science, and Cochrane CENTRAL databases were searched from their inception to February 22, 2019. According to the inclusion criteria, studies of the association between the methylation status of the GSTP1 gene promoter and prostate cancer were included. The difference in the incidence of GSTP1 promoter methylation in tissues, blood, or urine between patients with prostate cancer and those without prostate cancer were compared, and the results were expressed as the odds ratio (OR) and 95% confidence interval (CI). The pooled OR of each study was estimated using a fixed-effects model or a random-effects model to generate forest plots.

Results

Ultimately, 15 studies (1540 samples) were included. The estimated effect from our meta-analysis showed that the incidence of GSTP1 promoter methylation was higher in patients with prostate cancer than in those without prostate cancer (OR 18.58, 95% CI 9.60–35.95, P = 0.000). GSTP1 promoter methylation was highly correlated with the incidence of prostate cancer.

Conclusions

Methylation of the GSTP1 promoter may increase the risk of prostate cancer. This study may provide a strategic direction for prostate cancer research. Pending validation of these findings, the methylation of the GSTP1 promoter may be a potential biomarker to diagnose prostate cancer.

Keywords

Prostate cancer Glutathione-S-transferase p1 Methylation Meta-analysis 

Abbreviations

GSTP1

Glutathione-S-transferase P1

OR

Odds ratio

CI

Confidence interval

PSA

Prostate-specific antigen

PRISMA

Preferred reporting items for systematic reviews and meta-analyses

NOS

Newcastle–Ottawa Scale

MSP

Methylation-specific polymerase chain reaction

Q-MSP

Quantitative methylation-specific polymerase chain reaction

BPH

Benign prostatic hyperplasia

Notes

Acknowledgements

We would like to thank the Chinese Evidence Based Medicine Center at West China Hospital of Sichuan University for providing the Stata 14.0 statistical software.

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest regarding the present study.

Ethics approval and consent to participate

The article does not contain any studies with human participants performed by any of the authors.

Supplementary material

432_2019_2962_MOESM1_ESM.doc (42 kb)
Supplementary material 1 (DOC 42 kb)
432_2019_2962_MOESM2_ESM.doc (39 kb)
Supplementary material 2 (DOC 39 kb)

References

  1. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2006) Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 100:169–176.  https://doi.org/10.1007/s10549-006-9241-9 CrossRefPubMedGoogle Scholar
  2. Bastian PJ, Ellinger J, Schmidt D, Wernert N, Wellmann A, Muller SC, von Rucker A (2004) GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Eur J Med Res 9:523–527PubMedGoogle Scholar
  3. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefGoogle Scholar
  4. Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF (2002) The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol 167:1854–1858CrossRefPubMedGoogle Scholar
  5. Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF (2007) Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prevent 31:59–63.  https://doi.org/10.1016/j.cdp.2006.11.001 CrossRefPubMedGoogle Scholar
  6. Cook ED, Nelson AC (2011) Prostate cancer screening. Curr Oncol Rep 13:57–62.  https://doi.org/10.1007/s11912-010-0136-x CrossRefPubMedGoogle Scholar
  7. Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF (2013) Epigenetic susceptibility factors for prostate cancer with aging. Prostate 73:1721–1730.  https://doi.org/10.1002/pros.22716 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Dimitriadis E et al (2013) Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 33:191–197PubMedGoogle Scholar
  9. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58:4515–4518PubMedGoogle Scholar
  10. Fleshner K, Carlsson SV, Roobol MJ (2017) The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 14:26–37.  https://doi.org/10.1038/nrurol.2016.251 CrossRefGoogle Scholar
  11. Fukushige S, Horii A (2013) DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med 229:173–185CrossRefPubMedGoogle Scholar
  12. Hanson JA et al (2006) Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 98:255–261.  https://doi.org/10.1093/jnci/djj051 CrossRefPubMedGoogle Scholar
  13. Haroun RA, Zakhary NI, Mohamed MR, Abdelrahman AM, Kandil EI, Shalaby KA (2014) Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients. Asian Pacific J Cancer Prevent APJCP 15:4281–4287CrossRefGoogle Scholar
  14. Hashad DI, Hashad MM, Talaat IM, Ibrahim MA (2011) Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer. Genet Test Mol Biomark 15:667–670.  https://doi.org/10.1089/gtmb.2010.0262 CrossRefGoogle Scholar
  15. Jeronimo C et al (2002) I105 V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomark Prevent 11:445–450Google Scholar
  16. Kang GH, Lee S, Lee HJ, Hwang KS (2004) Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202:233–240.  https://doi.org/10.1002/path.1503 CrossRefPubMedGoogle Scholar
  17. Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, Cairns P (2004) Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10:28–32CrossRefPubMedGoogle Scholar
  18. Lan VT, Trang NT, Van DT, Thuan TB, Van To T, Linh VD, Uyen NQ (2015) A methylation-specific dot blot assay for improving specificity and sensitivity of methylation-specific PCR on DNA methylation analysis. Int J Clin Oncol 20:839–845.  https://doi.org/10.1007/s10147-014-0780-5 CrossRefPubMedGoogle Scholar
  19. Mahapatra S et al (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18:2882–2895.  https://doi.org/10.1158/1078-0432.CCR-11-2090 CrossRefPubMedGoogle Scholar
  20. Maldonado L et al (2014) GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol 192:1542–1548.  https://doi.org/10.1016/j.juro.2014.04.082 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Mancuso N, Gayther S, Gusev A (2018) Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nat Commun 9:4079.  https://doi.org/10.1038/s41467-018-06302-1 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Martignano F et al (2016a) GSTP1 Methylation and protein expression in prostate cancer: diagnostic implications. Dis Mark 2016:6.  https://doi.org/10.1155/2016/4358292 CrossRefGoogle Scholar
  23. Martignano F et al (2016b) GSTP1 methylation and protein expression in prostate cancer: diagnostic implications. Dis Mark 2016:4358292.  https://doi.org/10.1155/2016/4358292 CrossRefGoogle Scholar
  24. Maruyama R et al (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8:514–519PubMedGoogle Scholar
  25. Massie CE et al (2015) HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr-Relat Cancer 22:131–144.  https://doi.org/10.1530/erc-14-0454 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Mian OY et al (2016) GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate 76:199–206.  https://doi.org/10.1002/pros.23111 CrossRefPubMedGoogle Scholar
  27. Miyake T et al (2012) GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci 103:913–920.  https://doi.org/10.1111/j.1349-7006.2012.02231.x CrossRefPubMedGoogle Scholar
  28. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097.  https://doi.org/10.1371/journal.pmed.1000097 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Nakamura J, Tanaka T, Kitajima Y, Noshiro H, Miyazaki K (2014) Methylation-mediated gene silencing as biomarkers of gastric cancer: a review. World J Gastroenterol 20:11991–12006.  https://doi.org/10.3748/wjg.v20.i34.11991 CrossRefPubMedPubMedCentralGoogle Scholar
  30. Pandey M, Shukla S, Gupta S (2010) Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer 126:2520–2533.  https://doi.org/10.1002/ijc.24988 CrossRefPubMedPubMedCentralGoogle Scholar
  31. Pongtheerat T, Pakdeethai S, Purisa W, Chariyalertsak S, Petmitr S (2011) Promoter methylation and genetic polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai breast-cancer patients. Asian Pac J Cancer Prevent APJCP 12:2731–2734Google Scholar
  32. Richiardi L, Fiano V, Grasso C, Zugna D, Delsedime L, Gillio-Tos A, Merletti F (2013) Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS one 8:e68162.  https://doi.org/10.1371/journal.pone.0068162 CrossRefPubMedPubMedCentralGoogle Scholar
  33. Rosenbaum E et al (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11:8321–8325.  https://doi.org/10.1158/1078-0432.CCR-05-1183 CrossRefPubMedGoogle Scholar
  34. Sanchez BE et al (2018) Using genetic and epigenetic markers to improve differential diagnosis of prostate cancer and benign prostatic hyperplasia by noninvasive methods in mexican patients. Clin Genitourin Cancer 16:e867–e877.  https://doi.org/10.1016/j.clgc.2018.02.004 CrossRefPubMedGoogle Scholar
  35. Saxena A et al (2012) GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp Ther Med 4:1097–1103.  https://doi.org/10.3892/etm.2012.710 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Siegel RL, Miller KD, Jemal A (2018) Jemal A. Cancer statistics 2018(68):7–30.  https://doi.org/10.3322/caac.21442 CrossRefGoogle Scholar
  37. Stuck AE, Rubenstein LZ, Wieland D (1998) Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ (Clinical research ed) 316:469 (author reply 470–461) CrossRefPubMedCentralGoogle Scholar
  38. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 CrossRefPubMedGoogle Scholar
  39. Trock BJ et al (2012) Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 110:56–62.  https://doi.org/10.1111/j.1464-410x.2011.10718.x CrossRefPubMedGoogle Scholar
  40. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W (2012) The epigenetic promise for prostate cancer diagnosis. Prostate 72:1248–1261.  https://doi.org/10.1002/pros.22459 CrossRefPubMedGoogle Scholar
  41. Vo TT, Ta BT, Ta VT, Vuong DL, Nguyen QU (2016) Promoter methylation profile of GSTP1 and RASSF1A in prostate cancer and benign hyperplasia in Vietnamese men. Turk J Med Sci 46:228–235.  https://doi.org/10.3906/sag-1410-65 CrossRefPubMedGoogle Scholar
  42. Wallis CJD et al (2016) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70:21–30.  https://doi.org/10.1016/j.eururo.2015.11.010 CrossRefPubMedGoogle Scholar
  43. Zhang W et al (2015) Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer. Mol Med Rep 12:141–146.  https://doi.org/10.3892/mmr.2015.3402 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Interventional RadiologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of NeurologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations